(R)-tert-Butyl (1-(ethylamino)-1-oxopropan-2-yl)carbamate | 1101135-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-tert-Butyl (1-(ethylamino)-1-oxopropan-2-yl)carbamate
• 英文别名: Tert-butyl N-[1-(ethylcarbamoyl)ethyl]carbamate；tert-butyl N-[1-(ethylamino)-1-oxopropan-2-yl]carbamate
• CAS: 1101135-76-5
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: IUYXQFLOYFCQKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST
  申请人：Napolitano Elio

  公开号：US20090292129A1

  公开（公告）日：2009-11-26

  A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex of the resolving agent and an enantiomer of interest, c) separating the enantiomer of interest from the obtained diastereoisomer, wherein such a process is characterized in that said resolving agent is a compound of Formula (I). A diastereoisomeric complex between the resolving agent of Formula (I) and the enantiomer of interest is also described. The process according to the invention allows acid and basic racemic mixtures to be separated.

  本发明提供了一种用于分离外消旋化合物的方法，包括以下步骤：a）将外消旋化合物与分离剂反应，b）形成分离剂和所需对映体的非对映异构体复合物，c）从所得的非对映异构体中分离所需对映体。其中，所述分离剂为式（I）的化合物。本发明还描述了分离剂式（I）与所需对映体之间的非对映异构体复合物。本发明所述方法可以分离酸性和碱性外消旋混合物。
• CHEMICAL COMPOUNDS
  申请人：Cowen Scott

  公开号：US20100197749A1

  公开（公告）日：2010-08-05

  The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  本发明涉及公式(I)和(II)的化合物，或其药学上可接受的盐，具有Edg-1拮抗活性，因此在抗癌活性方面有用，并且在人体或动物体的治疗方法中使用。本发明还涉及制造上述化合物的过程，包含它们的制药组合物以及它们在制造用于在诸如人类之类的恒温动物中产生抗癌效应的药物中的用途。
• THERAPEUTIC COMPOUNDS
  申请人：LaVoie Edmond J.

  公开号：US20120046234A1

  公开（公告）日：2012-02-23

  The invention provides compounds of formula I, II, and III as defined herein, as well as salts thereof. The compounds may have activity as anti-proliferative agents.
• MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE
  申请人：Yale University

  公开号：US20200121684A1

  公开（公告）日：2020-04-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound includes a Von Hippel-Lindau, Cereblon, Inhibitors of Apotosis Proteins, or Mouse Double-Minute Homolog 2 ligand that binds to the respective E3 ubiquitin ligase. The other end of a bifunctional compound includes a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein can be treated or prevented with compounds and compositions of the present disclosure.
• US8993607B2
  申请人：——

  公开号：US8993607B2

  公开（公告）日：2015-03-31